Sysmex Corporation ADR (OTCMKTS:SSMXY) Sees Significant Increase in Short Interest

Sysmex Corporation ADR (OTCMKTS:SSMXY) saw a significant growth in short interest during the month of March. As of March 13th, there was short interest totaling 87,678 shares, a growth of 111.6% from the February 26th total of 41,438 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 591,040 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Citigroup lowered shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 16th. One equities research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold”.

Sysmex Stock Performance

SSMXY opened at $8.40 on Friday. The company has a current ratio of 3.33, a quick ratio of 2.44 and a debt-to-equity ratio of 0.12. The business’s 50 day moving average is $9.14 and its 200-day moving average is $10.28. The stock has a market cap of $5.29 billion, a PE ratio of 17.50 and a beta of 1.14. Sysmex has a twelve month low of $8.15 and a twelve month high of $19.65.

Sysmex (OTCMKTS:SSMXY) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.01. The business had revenue of $837.32 million during the quarter, compared to analyst estimates of $819.99 million. Sysmex had a return on equity of 9.27% and a net margin of 8.86%. On average, analysts predict that Sysmex will post 0.57 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.